keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson's and PET scan

keyword
https://www.readbyqxmd.com/read/28579485/cerebral-metabolic-change-in-parkinson-s-disease-patients-with-anxiety-a-fdg-pet-study
#1
Xixi Wang, Jiejin Zhang, Yongsheng Yuan, Tiannv Li, Li Zhang, Jian Ding, Siming Jiang, Junyi Li, Lin Zhu, Kezhong Zhang
OBJECT: To detect the cerebral metabolic bases of Parkinson's disease (PD) patients with anxiety. METHODS: Totally 28 idiopathic PD patients without depression (17-item Hamilton Depression Rating Scale, HAMD score <14) were enrolled in our study. All subjects were classified into PD with anxiety (PD-A) (n=13) and PD without anxiety (PD-NA) (n=15) by cutoff score of 11 according to Hamilton Anxiety Rating Scale (HAMA). Besides, age- and gender- matched healthy controls (HCs) (n=15) were selected...
June 1, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28568506/pbb3-imaging-in-parkinsonian-disorders-evidence-for-binding-to-tau-and-other-proteins
#2
Alexandra Perez-Soriano, Julieta E Arena, Katie Dinelle, Qing Miao, Jessamyn McKenzie, Nicole Neilson, Andreas Puschmann, Paul Schaffer, Hitoshi Shinotoh, Jenna Smith-Forrester, Elham Shahinfard, Nasim Vafai, Daryl Wile, Zbigniew Wszolek, Makoto Higuchi, Vesna Sossi, A Jon Stoessl
BACKGROUND AND OBJECTIVES: To study selective regional binding for tau pathology in vivo, using PET with [(11) C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy. METHODS: Dynamic PET scans were obtained for 70 minutes after the bolus injection of [(11) C]PBB3 in 5 PSP subjects, 1 subject with DCTN1 mutation and PSP phenotype, 3 asymptomatic SNCA duplication carriers, 1 MSA subject, and 6 healthy controls of similar age. Tissue reference Logan analysis was applied to each region of interest using a cerebellar white matter reference region...
June 1, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28542444/regional-brain-amyloid-%C3%AE-accumulation-associates-with-domain-specific-cognitive-performance-in-parkinson-disease-without-dementia
#3
Rizwan S Akhtar, Sharon X Xie, Yin J Chen, Jacqueline Rick, Rachel G Gross, Ilya M Nasrallah, Vivianna M Van Deerlin, John Q Trojanowski, Alice S Chen-Plotkin, Howard I Hurtig, Andrew D Siderowf, Jacob G Dubroff, Daniel Weintraub
Parkinson disease patients develop clinically significant cognitive impairment at variable times over their disease course, which is often preceded by milder deficits in memory, visuo-spatial, and executive domains. The significance of amyloid-β accumulation to these problems is unclear. We hypothesized that amyloid-β PET imaging by 18F-florbetapir, a radiotracer that detects fibrillar amyloid-β plaque deposits, would identify subjects with global cognitive impairment or poor performance in individual cognitive domains in non-demented Parkinson disease patients...
2017: PloS One
https://www.readbyqxmd.com/read/28490469/management-impact-of-imaging-brain-vesicular-monoamine-transporter-type-2-vmat2-in-clinically-uncertain-parkinsonian-syndrome-cups-with-18-f-av133-and-pet
#4
Paschal Kevin Alexander, Yennie Lie, Gareth Jones, Chomalaven Sivaratnam, Svetlana Bozinovski, Rachel S Mulligan, Kenneth Young, Victor Luis Villemagne, Christopher C Rowe
Objectives: Idiopathic Parkinson's disease (iPD) is a common neurodegenerative disorder where misdiagnosis occurs in up to 30% of patients after initial assessment and in 10-15% even after long-term follow-up. Vesicular monoamine transporter type II (VMAT2) imaging with Positron Emission Tomography (PET) allows assessment of the integrity of the presynaptic dopaminergic pathway. We investigated the management impact of VMAT2 imaging in patients with Clinically Uncertain Parkinsonian Syndromes (CUPS). Methods: Forty-seven patients with CUPS (56...
May 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28451991/-18-f-fp-dtbz-pet-study-in-a-lactacystin-treated-rat-model-of-parkinson-disease
#5
Chi-Chang Weng, Siao-Lan Huang, Zi-An Chen, Kun-Ju Lin, Ing-Tsung Hsiao, Tzu-Chen Yen, Mei-Ping Kung, Shiaw-Pyng Wey, Ching-Han Hsu
OBJECTIVE: Lactacystin has been used to establish rodent models of Parkinson disease (PD), with cerebral α-synuclein inclusions. This study evaluated the uptake of [(18)F]9-fluoropropyl-(+)-dihydrotetrabenazine ([(18)F]FP-(+)-DTBZ), a vesicular monoamine transporter type 2 (VMAT2)-targeting radiotracer, through positron emission tomography (PET) in lactacystin-treated rat brains. METHODS: Adult male Sprague-Dawley rats were randomly treated with a single intracranial dose of lactacystin (2 or 5 μg) or saline (served as the sham control) into the left medial forebrain bundle...
April 27, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28440890/fluorescence-and-autoradiographic-evaluation-of-tau-pet-ligand-pbb3-to-%C3%AE-synuclein-pathology
#6
Shunsuke Koga, Maiko Ono, Naruhiko Sahara, Makoto Higuchi, Dennis W Dickson
BACKGROUND: The tau PET ligand 2-((1E,3E)-4-(6-([(11) C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([(11) C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [(11) C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. METHOD: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden...
April 25, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28407307/adenosine-a1-receptors-measured-with-11-c-mpdx-pet-in-early-parkinson-s-disease
#7
Masahiro Mishina, Kenji Ishii, Yuichi Kimura, Masahiko Suzuki, Shin Kitamura, Kenji Ishibashi, Muneyuki Sakata, Keiichi Oda, Shiro Kobayashi, Kazumi Kimura, Kiichi Ishiwata
Adenosine A1 receptors (A1 Rs) interact negatively with dopamine D1 receptors (D1 Rs) in neurons of the basal ganglia's direct pathway, while adenosine A2A receptors (A2A Rs) negatively interact with dopamine D2 receptors (D2 Rs) in indirect-pathway neurons. The aim of this study was to investigate the cerebral density of A1 Rs in Parkinson's disease (PD) in its early stages, using PET scans with the radioligand 8-dicyclopropylmethyl-1-(11) C-methyl-3-propylxanthine ((11) C-MPDX). We studied 10 drug-naïve patients with early PD...
August 2017: Synapse
https://www.readbyqxmd.com/read/28386687/abnormal-metabolic-brain-network-associated-with-parkinson-s-disease-replication-on-a-new-european-sample
#8
Petra Tomše, Luka Jensterle, Marko Grmek, Katja Zaletel, Zvezdan Pirtošek, Vijay Dhawan, Shichun Peng, David Eidelberg, Yilong Ma, Maja Trošt
PURPOSE: The purpose of this study was to identify the specific metabolic brain pattern characteristic for Parkinson's disease (PD): Parkinson's disease-related pattern (PDRP), using network analysis of [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) brain images in a cohort of Slovenian PD patients. METHODS: Twenty PD patients (age 70.1 ± 7.8 years, Movement Disorder Society Unified Parkinson's Disease Motor Rating Scale (MDS-UPDRS-III) 38.3 ± 12...
May 2017: Neuroradiology
https://www.readbyqxmd.com/read/28378615/the-utility-of-fdg-pet-in-the-differential-diagnosis-of-parkinsonism
#9
Leposava Brajkovic, Vladimir Kostic, Dragana Sobic-Saranovic, Elka Stefanova, Milica Jecmenica-Lukic, Ana Jesic, Milica Stojiljkovic, Strahinja Odalovic, Francesca Gallivanone, Isabella Castiglioni, Branislava Radovic, Goran Trajkovic, Vera Artiko
INTRODUCTION: Differential diagnosis of parkinsonian disorders can be difficult on clinical grounds, especially in the early stage. Recent advancements in 18-F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging reveals different patterns of regional glucose metabolism in idiopathic Parkinson's disease (IPD) and atypical parkinsonian syndromes, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), which may help differentiating between these conditions...
April 5, 2017: Neurological Research
https://www.readbyqxmd.com/read/28336296/serotonin-and-dopamine-transporter-pet-changes-in-the-premotor-phase-of-lrrk2-parkinsonism-cross-sectional-studies
#10
Daryl J Wile, Pankaj A Agarwal, Michael Schulzer, Edwin Mak, Katherine Dinelle, Elham Shahinfard, Nasim Vafai, Kazuko Hasegawa, Jing Zhang, Jessamyn McKenzie, Nicole Neilson, Audrey Strongosky, Ryan J Uitti, Mark Guttman, Cyrus P Zabetian, Yu-Shin Ding, Mike Adam, Jan Aasly, Zbigniew K Wszolek, Matthew Farrer, Vesna Sossi, A Jon Stoessl
BACKGROUND: People with Parkinson's disease can show premotor neurochemical changes in the dopaminergic and non-dopaminergic systems. Using PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutation carriers with Parkinson's disease and individuals with sporadic Parkinson's disease, and whether LRRK2 mutation carriers without motor symptoms show PET changes. METHODS: We did two cross-sectional PET studies at the Pacific Parkinson's Research Centre in Vancouver, BC, Canada...
May 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28315844/cerebral-glucose-metabolism-and-cognition-in-newly-diagnosed-parkinson-s-disease-icicle-pd-study
#11
M J Firbank, A J Yarnall, R A Lawson, G W Duncan, T K Khoo, G S Petrides, J T O'Brien, R A Barker, R J Maxwell, D J Brooks, D J Burn
OBJECTIVE: To assess reductions of cerebral glucose metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their associations with cognitive decline. METHODS: FDG-PET was performed on a cohort of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls. PD participants were scanned while on their usual dopaminergic medication. Cognitive testing was performed at baseline, and after 18 months using the Cognitive Drug Research (CDR) and Cambridge Neuropsychological Test Automated Battery (CANTAB) computerised batteries, the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA)...
April 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28257461/quantitative-analysis-of-the-therapeutic-effect-of-magnolol-on-mptp-induced-mouse-model-of-parkinson-s-disease-using-in-vivo-18f-9-fluoropropyl-dihydrotetrabenazine-pet-imaging
#12
Chi-Chang Weng, Zi-An Chen, Ko-Ting Chao, Ting-Wei Ee, Kun-Ju Lin, Ming-Huan Chan, Ing-Tsung Hsiao, Tzu-Chen Yen, Mei-Ping Kung, Ching-Han Hsu, Shiaw-Pyng Wey
18F-9-Fluoropropyl-(+)-dihydrotetrabenazine [18F-FP-(+)-DTBZ] positron emission tomography (PET) has been shown to detect dopaminergic neuron loss associated with Parkinson's disease (PD) in human and neurotoxin-induced animal models. A polyphenol compound, magnolol, was recently proposed as having a potentially restorative effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- or 6-hydroxydopamine-treated animal models. In this study, 18F-FP-(+)-DTBZ PET was used to determine the therapeutic efficacy of magnolol in an MPTP-PD mouse model that was prepared by giving an intraperitoneally (i...
2017: PloS One
https://www.readbyqxmd.com/read/28253276/clinical-and-neuroimaging-characteristics-of-chinese-dementia-with-lewy-bodies
#13
Shuai Liu, Xiao-Dan Wang, Ying Wang, Zhihong Shi, Li Cai, Shuling Liu, Tong Han, Yuying Zhou, Xinping Wang, Shuo Gao, Yong Ji
Dementia with Lewy bodies (DLB) is the second most common subtype of degenerative dementia. To our knowledge, available information about the clinical features of DLB in China remains limited. Our study therefore aimed to address this issue. Thirty-seven Chinese patients with probable DLB were recruited for this study. All subjects underwent neuropsychological assessment by trained neurologists, as well as undergoing MRI, 11C-PIB PET scans for Aβ deposition and 18F-FDG PET scans for regional cerebral glucose metabolism...
2017: PloS One
https://www.readbyqxmd.com/read/28188080/the-effect-of-18f-fdg-pet-image-reconstruction-algorithms-on-the-expression-of-characteristic-metabolic-brain-network-in-parkinson-s-disease
#14
Petra Tomše, Luka Jensterle, Sebastijan Rep, Marko Grmek, Katja Zaletel, David Eidelberg, Vijay Dhawan, Yilong Ma, Maja Trošt
PURPOSE: To evaluate the reproducibility of the expression of Parkinson's Disease Related Pattern (PDRP) across multiple sets of 18F-FDG-PET brain images reconstructed with different reconstruction algorithms. METHODS: 18F-FDG-PET brain imaging was performed in two independent cohorts of Parkinson's disease (PD) patients and normal controls (NC). Slovenian cohort (20 PD patients, 20 NC) was scanned with Siemens Biograph mCT camera and reconstructed using FBP, FBP+TOF, OSEM, OSEM+TOF, OSEM+PSF and OSEM+PSF+TOF...
February 7, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28170002/regulation-of-dopaminergic-function-an-18-f-dopa-pet-apomorphine-challenge-study-in-humans
#15
S Jauhar, M Veronese, M Rogdaki, M Bloomfield, S Natesan, F Turkheimer, S Kapur, O D Howes
Dopaminergic function has a key role in normal brain function, dopaminergic dysfunction being implicated in numerous neuropsychiatric disorders. Animal studies show that dopaminergic stimulation regulates dopaminergic function, but it is not known whether this exists in humans. In the first study (study 1), we measured dopamine synthesis capacity (indexed as Ki(cer)) to identify the relationship between baseline and change in Ki(cer) under resting conditions for comparison with effects of dopaminergic stimulation...
February 7, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/27990313/deep-brain-stimulation-of-a-patient-with-psychogenic-movement-disorder
#16
Jean-Philippe Langevin, Jesse M Skoch, Scott J Sherman
BACKGROUND: The long-term safety of deep brain stimulation (DBS) is an important issue because new applications are being investigated for a variety of disorders. Studying instances where DBS was inadvertently implanted in patients without a movement disorder may provide information about the safety of the therapy. We report the case of a patient with a psychogenic movement disorder treated with deep brain stimulation (DBS). CASE DESCRIPTION: The patient presented at our clinic after 5 years of chronic DBS of the subthalamic nucleus (STN) for presumed Parkinson's disease...
2016: Surgical Neurology International
https://www.readbyqxmd.com/read/27914043/a-revisit-to-quantitative-pet-with-18-f-fdopa-of-high-specific-activity-using-a-high-resolution-condition-in-view-of-application-to-regenerative-therapy
#17
Go Akamatsu, Akihito Ohnishi, Kazuki Aita, Hiroyuki Nishida, Yasuhiko Ikari, Masahiro Sasaki, Nobuo Kohara, Michio Senda
OBJECTIVE: With the advent of regenerative/cell therapy for Parkinson's disease (PD), (18)F-FDOPA has drawn new attention as a biomarker of the therapeutic that cannot be evaluated with radiopharmaceuticals for dopamine transporter. Since most previous (18)F-FDOPA PET studies were carried out many years ago with a PET scanner of lower resolution and with (18)F-FDOPA of low specific activity synthesized from (18)F-F2, we used a newer PET/CT scanner with a high-resolution condition and (18)F-FDOPA synthesized from (18)F-F(-) to re-evaluate this technique on normal subjects and patients with PD, together with D2 receptor imaging with (11)C-raclopride (RAC)...
February 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/27893588/suite-pet-ct-neuroimaging-for-the-diagnosis-of-parkinson-s-disease-statistical-parametric-mapping-analysis
#18
Ruimin Wang, Baixuan Xu, Zhe Guo, Tong Chen, Jinming Zhang, Yingmao Chen, Haiyan Zhu
OBJECTIVES: The aim of this study was to investigate the topographical distribution of dopamine transporter (DAT), dopamine D2 receptor, and glucose metabolism in Parkinson's disease (PD) using PET/computed tomography (CT) scanning and statistical parametric mapping (SPM) analysis. PARTICIPANTS AND METHODS: Seventy-four patients (58 PD patients and 16 normal controls) underwent DAT, D2 receptor, and glucose brain PET/CT scans using C-methyl-N-2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane (C-β-CFT), C-raclopride (C-RAC), and fluorine-18-fluorodeoxyglucose (F-FDG) radiotracers for the respective scans...
February 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27862279/pet-and-mri-detection-of-early-and-progressive-neurodegeneration-in-spinocerebellar-ataxia-type-36
#19
Pablo Aguiar, Julio Pardo, Manuel Arias, Beatriz Quintáns, Montse Fernández-Prieto, Rocío Martínez-Regueiro, José-Manuel Pumar, Jesús Silva-Rodríguez, Álvaro Ruibal, María-Jesús Sobrido, Julia Cortés
BACKGROUND: The spinocerebellar ataxias (SCAs) form a clinically, genetically, and pathological heterogeneous group of autosomal-dominant degenerative diseases. In particular, SCA36 is characterized by a late-onset, slowly progressive cerebellar syndrome typically associated with sensorineural hearing loss. This study was aimed at analyzing the neurodegenerative process underlying SCA36 through fluorodeoxyglucose positron emission tomography (FDG-PET) and MRI scans. METHODS: Twenty SCA36 patients underwent a study consisting of FDG-PET and MRI scans...
February 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/27859651/sustained-striatal-dopamine-levels-following-intestinal-levodopa-infusions-in-parkinson-s-disease-patients
#20
Marios Politis, Anna Sauerbier, Clare Loane, Nicola Pavese, Anne Martin, Benjamin Corcoran, David J Brooks, K Ray-Chaudhuri, Paola Piccini
BACKGROUND: The objective of this study was to investigate in vivo the ability of levodopa/carbidopa intestinal gel infusions to produce sustained striatal dopamine levels and to improve clinical outcomes in Parkinson's disease patients. METHODS: Six advanced Parkinson's disease patients had serial [(11) C]raclopride PET to assess levodopa/carbidopa intestinal gel infusion-induced rises in striatal dopamine as reflected by a fall in dopamine-D2/3 receptor availability...
February 2017: Movement Disorders: Official Journal of the Movement Disorder Society
keyword
keyword
60911
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"